| Cash Flow | 2025-08-31 | 2025-05-31 |
|---|---|---|
| Net income | 1,388,048 | 638,640 |
| Depreciation and amortization expense | 742,231 | 498,141 |
| Impairment of investment - tianhe stock | 0 | 0 |
| Loss on sale of property and equipment | -48,304 | -47,671 |
| Losses (gains) on marketable securities | -604,619 | -410,733 |
| Unrealized gain on interest rate swap contract | 0 | 0 |
| Compensatory element of stock options | 374,198 | 337,418 |
| Provision for doubtful accounts | 780,197 | 366,586 |
| Amortization of debt issuance costs | 15,657 | 10,465 |
| Amortization of operating lease right-of-use asset | 295,654 | 186,114 |
| Accounts receivable | 304,483 | -11,034 |
| Prepaid expenses | -19,125 | -15,710 |
| Inventory | -79,730 | -58,219 |
| Other current assets | -109,604 | -62,265 |
| Deposits and other assets, net | 92,144 | 61,694 |
| Accounts payable | 741,407 | 370,932 |
| Accrued expenses | -3,525,297 | -3,136,174 |
| Operating lease liability | -317,744 | -203,016 |
| Other liabilities | 0 | 0 |
| Deferred revenue | 3,238,687 | 2,048,033 |
| Net cash from operating activities | 4,197,793 | 1,661,077 |
| Purchases of property and equipment | 163,249 | 124,461 |
| Sale of property and equipment | 115,000 | 115,000 |
| Payment of duke license agreement | 0 | 0 |
| Proceeds from liquidation of marketable securities | 0 | - |
| Purchases of marketable securities | 3,160,145 | 2,574,249 |
| Sale of marketable securities | 2,522,711 | 793,426 |
| Net cash used in investing activities | -685,683 | -1,790,284 |
| Treasury stock purchases | 169,502 | 88,619 |
| Repayments of note payable | 110,235 | 74,416 |
| Repayment of line of credit | 7,120,000 | 3,700,000 |
| Proceeds from the exercise of stock options | 23,101 | - |
| Proceeds from line of credit | 6,800,000 | 6,800,000 |
| Dividends paid | 3,231,227 | 3,231,227 |
| Proceeds from swap termination | 0 | 0 |
| Net cash used in financing activities | -3,807,863 | -294,262 |
| Decrease in cash and cash equivalents | -295,753 | -423,469 |
| Cash and cash equivalents at beginning of period | 560,960 | - |
| Cash and cash equivalents at end of period | 265,207 | - |
CRYO CELL INTERNATIONAL INC (CCEL)
CRYO CELL INTERNATIONAL INC (CCEL)